Sub-anesthetic ketamine produces rapid antidepressant effects in patients with bipolar and unipolar major depression where conventional monoaminergic-based antidepressant drugs have been ineffective or ridden with side effects. A single ketamine infusion can produce antidepressant effects lasting up to two weeks, and multiple ketamine infusions prolong this effect. Pre-clinical studies are underway to uncover ketamine's mechanisms of action, but there are still many questions unanswered regarding the safety of its long-term use. Abuse liability is one area of concern, as recreational ketamine use is an ongoing issue in many parts of the world. Another understudied area is sex differences in responsivity to ketamine. Women are twice as likely as men to be diagnosed with depression, and they progress through stages of drug addiction more rapidly than their male counterparts. Despite this, preclinical studies in ketamine's antidepressant and addictive-like behaviors in females are limited. These intersecting factors in recent clinical and pre-clinical studies are reviewed to characterize ketamine's therapeutic potential, its limitations, and its potential mechanisms of action.
Introduction
Major depressive disorder is a multi-symptom condition that contributes significantly to the global burden of disease, and women have a twofold higher risk of depression than men [1] . Treatment efforts have been hindered by monoaminergic-based antidepressants that have undesirable side effects and poor efficacy [2] . Therefore, the discovery that ketamine produces rapid antidepressant effects has generated much optimism in the field of psychiatry and neuroscience. While classical antidepressants take several weeks of daily administration to produce an effect, sub-anesthetic ketamine infusions alleviates depressive symptoms hours after the first infusion, lasting approximately 7-14 days in patients with treatment-resistant depression [3] . Furthermore, ketamine rapidly alleviates suicidal ideation, conferring a unique use of ketamine in the emergency room [4] . These findings, however, must be tempered by a number of notable limitations in our knowledge, especially that which pertains to the safety and efficacy of chronic long-term ketamine treatment, which has not been sufficiently addressed in clinical trials [5 ] . Indeed, consequences of long-term exposure to ketamine have only been assessed in recreational contexts, as ketamine is used as a popular club drug because of its euphoric effects and vivid dissociative hallucinations. Importantly, recreational ketamine use differs greatly from antidepressant ketamine in terms of dose (higher), route of administration (typically intranasal), and setting (a rave or club). Nevertheless, few studies have assessed sex differences in ketamine responsivity. The inclusion of sex as a factor improves the translatability of preclinical research, and it may uncover important sex differences with implications for the abuse liability of antidepressant ketamine. Therefore, the purpose of this review is to bridge clinical and preclinical research to summarize what is known and to identify knowledge gaps regarding sex differences in ketamine response within the context of depression and recreational ketamine use.
Sex differences in stress and ketamine's antidepressant effects
While females are included in clinical research, few studies investigating ketamine's antidepressant effects analyze sex as a variable. A recent meta-regression analysis of six studies (n = 103) found that sex, age, and drug use history did not contribute to ketamine efficacy [6] . A larger meta-analysis analyzed 21 studies (n = 437) at four different time points, and they found no effect of sex at the 4 hours and 24 hours time points; only at the 7 day time point was having a greater proportion of male subjects predictive of overall higher efficacy [7] . These findings are limited to a relatively short time frame and only tested one acute ketamine dose (0.5 mg/kg/40 min intravenous infusion). To date, no clinical studies have looked at dose-dependent differences in ketamine efficacy in men and women, nor has repeated ketamine infusions been analyzed by sex. 
